相似文献
1
Thiazolidinediones: do harms outweigh benefits?
CMAJ. 2009 Jan 6;180(1):16-7. doi: 10.1503/cmaj.081713. Epub 2008 Dec 10.
2
Thiazolidinedione use and the risk of fractures.
CMAJ. 2009 Apr 14;180(8):841-2; author reply 842-3. doi: 10.1503/cmaj.1090003.
3
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
CMAJ. 2009 Jan 6;180(1):32-9. doi: 10.1503/cmaj.080486. Epub 2008 Dec 10.
4
Thiazolidinedione use and the risk of fractures.
CMAJ. 2009 Apr 14;180(8):841. doi: 10.1503/cmaj.1090005.
5
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
Diabetes Obes Metab. 2010 Aug;12(8):716-21. doi: 10.1111/j.1463-1326.2010.01225.x.
6
Rosiglitazone and pioglitazone. Beware fractures.
BMJ. 2009 Sep 29;339:b3957. doi: 10.1136/bmj.b3957.
7
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Dtsch Med Wochenschr. 2007 Dec;132(49):2650-3. doi: 10.1055/s-2007-993115.
8
Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
J Clin Endocrinol Metab. 2010 Oct;95(10):4560-5. doi: 10.1210/jc.2009-2638. Epub 2010 Jul 14.
9
The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
PLoS Med. 2009 Sep;6(9):e1000154. doi: 10.1371/journal.pmed.1000154. Epub 2009 Sep 29.
10
The safety of rosiglitazone in the treatment of type 2 diabetes.
Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579.
引用本文的文献
1
Advancement of artificial intelligence based treatment strategy in type 2 diabetes: A critical update.
J Pharm Anal. 2025 Jun;15(6):101305. doi: 10.1016/j.jpha.2025.101305. Epub 2025 Apr 10.
2
Clustering of the metabolic syndrome components in adolescence: role of visceral fat.
PLoS One. 2013 Dec 20;8(12):e82368. doi: 10.1371/journal.pone.0082368. eCollection 2013.
3
Prescription pattern of chinese herbal products for diabetes mellitus in taiwan: a population-based study.
Evid Based Complement Alternat Med. 2013;2013:201329. doi: 10.1155/2013/201329. Epub 2013 Jun 17.
4
Double-blind, placebo-controlled clinical evaluation of an Ayurvedic formulation (GlucoCare capsules) in non-insulin dependent diabetes mellitus.
J Ayurveda Integr Med. 2010 Jan;1(1):45-51. doi: 10.4103/0975-9476.59827.
5
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Drugs. 2010 Oct 22;70(15):2051-72. doi: 10.2165/11205080-000000000-00000.
6
Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.
Circ Res. 2010 Feb 5;106(2):409-17. doi: 10.1161/CIRCRESAHA.109.211797. Epub 2009 Nov 25.
7
Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?
Bone. 2010 Jan;46(1):13-7. doi: 10.1016/j.bone.2009.07.083. Epub 2009 Aug 5.
8
Complementary and alternative medicine for the treatment of type 2 diabetes.
Can Fam Physician. 2009 Jun;55(6):591-6.
9
Safety and efficacy of rosiglitazone in the elderly diabetic patient.
Vasc Health Risk Manag. 2009;5(1):389-95. doi: 10.2147/vhrm.s4053.
10
Thiazolidinedione use and the risk of fractures.
CMAJ. 2009 Apr 14;180(8):841. doi: 10.1503/cmaj.1090005.
本文引用的文献
1
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
CMAJ. 2009 Jan 6;180(1):32-9. doi: 10.1503/cmaj.080486. Epub 2008 Dec 10.
2
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
JAMA. 2007 Dec 12;298(22):2634-43. doi: 10.1001/jama.298.22.2634.
3
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Lancet. 2007 Sep 29;370(9593):1129-36. doi: 10.1016/S0140-6736(07)61514-1.
4
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
JAMA. 2007 Sep 12;298(10):1189-95. doi: 10.1001/jama.298.10.1189.
5
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
JAMA. 2007 Sep 12;298(10):1180-8. doi: 10.1001/jama.298.10.1180.
6
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21.
7
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet. 2005 Oct 8;366(9493):1279-89. doi: 10.1016/S0140-6736(05)67528-9.
8
Thiazolidinediones.
N Engl J Med. 2004 Sep 9;351(11):1106-18. doi: 10.1056/NEJMra041001.
Zotero 插件